Please login to the form below

Not currently logged in
Email:
Password:

medicines access

This page shows the latest medicines access news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE’s initial verdict comes shortly after the Medicines and Healthcare Products Regulatory Agency (MHRA) made the therapy available to UK patients with atopic dermatitis via its Early Access to Medicines ... initial assessment, ”commented Jessamy

Latest news

  • Ex-GSK CEO Witty named head of pharmacy benefit firm Optum Ex-GSK CEO Witty named head of pharmacy benefit firm Optum

    Witty - under whose leadership GSK topped the charts for access to medicines for several years in a row and who repeatedly told the industry that a new pricing approach was needed - ... companies when it comes to trading off price for access to

  • CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

    Until now, Raxone was made available to patients via the early access medicines  scheme (EAMS) under an ‘exceptional circumstance’, which comes about when an applicant can show they are unable to ... There has been no word on whether patients

  • The shifting healthcare landscape The shifting healthcare landscape

    With more personalised medicines targeting specific patient groups, payers cannot apply the old funding approach but need to find new ways to reward innovation. ... patients with access to medicines is key.

  • AMR research 'under threat' due to lack of economic incentives AMR research 'under threat' due to lack of economic incentives

    When it comes to access, vast amounts of antibiotics are taken by patients and animals that don’t need them, while at the same time almost six million people die each ... year from infections because they don’t have access to these medicines.

  • MHRA: No change for pre-Brexit products after UK exits the EU MHRA: No change for pre-Brexit products after UK exits the EU

    That’s according to the Medicines and Healthcare products Regulatory Agency (MHRA), which moved this week to provide a measure of regulatory clarity before second phase of Brexit talks begin. ... continued access to best and most innovative medicines

More from news
Approximately 4 fully matching, plus 423 partially matching documents found.

Latest Intelligence

  • Brexit Means Brexit Brexit Means Brexit

    Maintaining membership would, she said, assure a continuation of investment in innovative medicines in the UK. ... But it should also begin, privately at least, to stress the potential consumer impacts an alternative position might bring; the

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    But our approach and success also hinges on patients being able to access our medicines. ... But only 5% of patients in England can currently access these medicines routinely through the NHS.

  • The challenges of making genomics a reality for patients today, not tomorrow The challenges of making genomics a reality for patients today, not tomorrow

    But our approach and success also hinges on patients being able to access our medicines. ... But only 5% of patients in England can currently access these medicines routinely through the NHS.

  • A marathon and a sprint A marathon and a sprint

    That can easily translate to pharma; medical can own some touchpoints, market access likewise and so on. ... A good example of this was a research trip to sub-Saharan Africa for the development of an access-to-medicines platform for oncology.

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    Right now, the access and reimbursement framework which has evolved in England is challenging, complex, and often duplicative, resulting in patients having slower access to significantly fewer important new medicines. ... The Government’s own data show

More from intelligence
Approximately 0 fully matching, plus 71 partially matching documents found.

Latest appointments

  • Pfizer’s Alan Maine moves to Edelman Pfizer’s Alan Maine moves to Edelman

    Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... During his time at Pfizer, Maine also

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    May’s new role will see her lead the biopharma’s commercial team in bringing Sobi ’s medicines to the country. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate

  • Inceptua Medicines Access appoints senior new-hires Inceptua Medicines Access appoints senior new-hires

    Inceptua Medicines Access appoints senior new-hires. The new speciality business unit appoints senior project manager and office manager. ... Multipharma’s new speciality business unit, Inceptua has appointed Ruth Rostron as its new senior project

  • Multipharma launches Inceptua Medicines Access Multipharma launches Inceptua Medicines Access

    Multipharma launches Inceptua Medicines Access. The group will be split into three sub-divisions. ... Multipharma has launched Inceptua Medicines Access, a speciality business unit that offers access to pre-approval and unlicensed medicines.

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. ... I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”.

More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest from PMHub

  • Unique forum will unite NHS and industry to drive innovation

    Unique forum will unite NHS and industry to drive innovation. HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at ... The event aims to help industry develop stronger

  • Accession

    A passion to harness the power of market access to ensure patients gain access to life changing medicines and devices. ... The early industry pioneers of market access, are the creative force behind Accession.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics